Ibopamine: Difference between revisions

	WikiDoc Resources for Ibopamine
Articles
Most recent articles on Ibopamine Most cited articles on Ibopamine Review articles on Ibopamine Articles on Ibopamine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ibopamine Images of Ibopamine Photos of Ibopamine Podcasts & MP3s on Ibopamine Videos on Ibopamine
Evidence Based Medicine
Cochrane Collaboration on Ibopamine Bandolier on Ibopamine TRIP on Ibopamine
Clinical Trials
Ongoing Trials on Ibopamine at Clinical Trials.gov Trial results on Ibopamine Clinical Trials on Ibopamine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ibopamine NICE Guidance on Ibopamine NHS PRODIGY Guidance FDA on Ibopamine CDC on Ibopamine
Books
Books on Ibopamine
News
Ibopamine in the news Be alerted to news on Ibopamine News trends on Ibopamine
Commentary
Blogs on Ibopamine
Definitions
Definitions of Ibopamine
Patient Resources / Community
Patient resources on Ibopamine Discussion groups on Ibopamine Patient Handouts on Ibopamine Directions to Hospitals Treating Ibopamine Risk calculators and risk factors for Ibopamine
Healthcare Provider Resources
Symptoms of Ibopamine Causes & Risk Factors for Ibopamine Diagnostic studies for Ibopamine Treatment of Ibopamine
Continuing Medical Education (CME)
CME Programs on Ibopamine
International
Ibopamine en Espanol Ibopamine en Francais
Business
Ibopamine in the Marketplace Patents on Ibopamine
Experimental / Informatics
List of terms related to Ibopamine

Ibopamine
Clinical data
ATC code	S01FB03 (WHO) ;
Identifiers
	IUPAC name 4-(2-(methylamino)ethyl)-1,2- phenylene bis(2-methylpropanoate);
CAS Number	66195-31-1;
PubChem CID	68555;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C17H25NO4
Molar mass	307.385 g/mol

VisualWikitext

Latest revision as of 00:29, 24 July 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ibopamine is a sympathomimetic drug, designed as a prodrug of epinine, used in ophthalmology.^[1] It induces mydriasis.^[2] It also has been investigated for use in the treatment of congestive heart failure.^[3]

It acts on D₁^[4]^[5] and α receptors as an agonist.^[6]

Ibopamine was first prepared by Casagrande and co-workers.^[7]

References

↑ Magacho L, Costa ML, Dessimoni A, de Avila MP (2006). "Comparison between the 1% and 2% ibopamine provocative test in primary open-angle glaucoma patients: sensitivity, specificity and tolerability". Arq Bras Oftalmol. 69 (5): 695–9. doi:10.1590/S0004-27492006000500015. PMID 17187138.
↑ Marchini G, Babighian S, Tosi R, Perfetti S, Bonomi L (June 2001). "Effects of 2% ibopamine on pupil, refraction, anterior segment anatomy and intraocular pressure". J Ocul Pharmacol Ther. 17 (3): 215–23. doi:10.1089/108076801750295254. PMID 11436942.
↑ van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH; et al. (November 1993). "Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)". J. Am. Coll. Cardiol. 22 (6): 1564–73. doi:10.1016/0735-1097(93)90579-P. PMID 7901256.
↑ Metra M, Missale C, Spano PF, Cas LD (May 1995). "Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine". J. Cardiovasc. Pharmacol. 25 (5): 732–40. doi:10.1097/00005344-199505000-00008. PMID 7630152.
↑ Lieverse AG, Girbes AR, Van Veldhuisen DJ; et al. (July 1995). "The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure". Eur. Heart J. 16 (7): 937–42. PMID 7498209.
↑ "IngentaConnect Ibopamine Stimulates -Adrenergic Receptors and D1 Dopaminergic Re..."
↑ C. Casagrande, F. Santangelo, C. Saini, F. Doggi, F. Gerli and O. Cerri (1986). "Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines-synthesis of ibopamine metabolites." Arzneimittelforschung 36 291-303.

Template:Cardiac stimulants excluding cardiac glycosides Template:Mydriatics and cycloplegics

[pmid17187138-1] Magacho L, Costa ML, Dessimoni A, de Avila MP (2006). "Comparison between the 1% and 2% ibopamine provocative test in primary open-angle glaucoma patients: sensitivity, specificity and tolerability". Arq Bras Oftalmol. 69 (5): 695–9. doi:10.1590/S0004-27492006000500015. PMID 17187138.

[pmid11436942-2] Marchini G, Babighian S, Tosi R, Perfetti S, Bonomi L (June 2001). "Effects of 2% ibopamine on pupil, refraction, anterior segment anatomy and intraocular pressure". J Ocul Pharmacol Ther. 17 (3): 215–23. doi:10.1089/108076801750295254. PMID 11436942.

[pmid7901256-3] van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH; et al. (November 1993). "Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)". J. Am. Coll. Cardiol. 22 (6): 1564–73. doi:10.1016/0735-1097(93)90579-P. PMID 7901256.

[pmid7630152-4] Metra M, Missale C, Spano PF, Cas LD (May 1995). "Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine". J. Cardiovasc. Pharmacol. 25 (5): 732–40. doi:10.1097/00005344-199505000-00008. PMID 7630152.

[pmid7498209-5] Lieverse AG, Girbes AR, Van Veldhuisen DJ; et al. (July 1995). "The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure". Eur. Heart J. 16 (7): 937–42. PMID 7498209.

[urlIngentaConnect_Ibopamine_Stimulates_-Adrenergic_Receptors_and_D1_Dopaminergic_Re...-6] "IngentaConnect Ibopamine Stimulates -Adrenergic Receptors and D1 Dopaminergic Re..."

[7] C. Casagrande, F. Santangelo, C. Saini, F. Doggi, F. Gerli and O. Cerri (1986). "Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines-synthesis of ibopamine metabolites." Arzneimittelforschung 36 291-303.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

@@ Line 26: / Line 26: @@
 }}
 __NOTOC__
+{{SI}}
 {{CMG}}
-{{Editor Join}}
+==Overview==
+'''Ibopamine''' is a [[sympathomimetic]] drug, designed as a [[prodrug]] of [[epinine]], used in [[ophthalmology]].<ref name="pmid17187138">{{cite journal |author=Magacho L, Costa ML, Dessimoni A, de Avila MP |title=Comparison between the 1% and 2% ibopamine provocative test in primary open-angle glaucoma patients: sensitivity, specificity and tolerability |journal=Arq Bras Oftalmol |volume=69 |issue=5 |pages=695–9 |year=2006 |pmid=17187138 |doi= 10.1590/S0004-27492006000500015|url=http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492006000500015&lng=en&nrm=iso&tlng=en}}</ref> It induces [[mydriasis]].<ref name="pmid11436942">{{cite journal |author=Marchini G, Babighian S, Tosi R, Perfetti S, Bonomi L |title=Effects of 2% ibopamine on pupil, refraction, anterior segment anatomy and intraocular pressure |journal=J Ocul Pharmacol Ther |volume=17 |issue=3 |pages=215–23 |date=June 2001 |pmid=11436942 |doi=10.1089/108076801750295254}}</ref> It also has been investigated for use in the treatment of [[congestive heart failure]].<ref name="pmid7901256">{{cite journal |author=van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH, ''et al.'' |title=Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT) |journal=J. Am. Coll. Cardiol. |volume=22 |issue=6 |pages=1564–73 |date=November 1993 |pmid=7901256 |doi= 10.1016/0735-1097(93)90579-P|url=}}</ref>
+It acts on [[Dopamine receptor D1|D<sub>1</sub>]]<ref name="pmid7630152">{{cite journal |author=Metra M, Missale C, Spano PF, Cas LD |title=Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine |journal=J. Cardiovasc. Pharmacol. |volume=25 |issue=5 |pages=732–40 |date=May 1995 |pmid=7630152 |doi= 10.1097/00005344-199505000-00008|url=}}</ref><ref name="pmid7498209">{{cite journal |author=Lieverse AG, Girbes AR, Van Veldhuisen DJ, ''et al.'' |title=The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure |journal=Eur. Heart J. |volume=16 |issue=7 |pages=937–42 |date=July 1995 |pmid=7498209 |doi= |url=http://eurheartj.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=7498209}}</ref> and  [[Adrenergic_receptor#.CE.B1_receptors|α]] receptors as an [[agonist]].<ref name="urlIngentaConnect Ibopamine Stimulates -Adrenergic Receptors and D1 Dopaminergic Re...">{{cite web |url=http://www.ingentaconnect.com/content/ben/cdth/2007/00000002/00000002/art00006 |title=IngentaConnect Ibopamine Stimulates -Adrenergic Receptors and D1 Dopaminergic Re... |format= |work= |accessdate=}}</ref>
+Ibopamine was first prepared by Casagrande and co-workers.<ref>C. Casagrande, F. Santangelo, C. Saini, F. Doggi, F. Gerli and O. Cerri (1986). "Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines-synthesis of ibopamine metabolites." ''Arzneimittelforschung''  '''36''' 291-303.</ref>
-==Overview==
-'''Ibopamine''' is a [[sympathomimetic]] used in [[ophthalmology]].
 == References ==
-{{refbegin}}
+{{reflist|2}}
-* The Merck Index, 12th Edition. 4921
-{{refend}}
+{{Cardiac stimulants excluding cardiac glycosides}}
 {{Mydriatics and cycloplegics}}
-[[Category:Drugs]]
+[[Category:Cardiovascular Drugs]]
+[[Category:Drug]]
-{{WikiDoc Help Menu}}
-{{WikiDoc Sources}}

Clinical data
ATC code	S01FB03 (WHO)
Identifiers
IUPAC name 4-(2-(methylamino)ethyl)-1,2- phenylene bis(2-methylpropanoate)
CAS Number	66195-31-1
PubChem CID	68555
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₇H₂₅NO₄
Molar mass	307.385 g/mol

Ibopamine: Difference between revisions

Latest revision as of 00:29, 24 July 2014

Overview

References

Navigation menu

Search